Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

NEXT STORY
Immuneering Added to the Nasdaq Biotechnology Index
PREV STORY
At 11.3% CAGR, Recombinant Vaccines Market Size [2021-2028] | is Expected to Reach USD 25.32 Billion
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma

author_avatar
NASDAQ Market News

Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics and Metabolism Reports

author_avatar
NASDAQ Market News

Global $6.6 Bn COVID-19 Drug Associated APIs Markets Analysis & Forecasts, 2015-2020, 2020-2025F, 2030F

author_avatar
NASDAQ Market News